bullish
Xtandi (Enzalutamide) – Second Generation Androgen Receptor (AR) Signalling Inhibitor
302 Views23 Dec 2016 15:01
While most of its peers struggle getting traction with new launches, Astellas is in a fortunate situation with its recently launched prostate...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Astellas (4503) - PROSPER Data Revives Value Story19 Sep 2017
- Xtandi (Enzalutamide) – Second Generation Androgen Receptor (AR) Signalling Inhibitor23 Dec 2016
x